Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Key Presentations on Acute Myeloid Leukemia From ASH 2020 Key Presentations on Acute Myeloid Leukemia From ASH 2020
Highlights in acute myeloid leukemia from ASH 2020 include study results for combination therapy in newly diagnosed AML patients with FLT-3, and CPX-351 vs 7 + 3 in older adults with secondary or high-risk-prognosis AML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Oral Azacitidine Benefits Some Older Adults With AML
TUESDAY, Dec. 29, 2020 -- For older patients with acute myeloid leukemia (AML) who are in remission after chemotherapy, those receiving maintenance therapy with the oral formulation of azacitidine (CC-486) versus placebo had longer overall and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news

Highlights in Acute Lymphoblastic Leukemia From ASH 2020 Highlights in Acute Lymphoblastic Leukemia From ASH 2020
Key studies from ASH 2020 on acute lymphoblastic leukemia include novel CAR T-cells, antibody-based therapies sequenced with chemotherapy, and residual disease monitoring with peripheral blood.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Drug offers hope for acute myeloid leukemia treatment in older adults
A new drug treatment for acute myeloid leukemia improves overall survival in those with the deadly blood cancer by up to 10 months, according to a clinical trial published by the New England Journal of Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 24, 2020 Category: Consumer Health News Source Type: news

Global trial reveals life saving drug for acute myeloid leukemia
(Monash University) Results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML), significantly improving survival in older patients, over the age of 55, with the disease. AML is the most acute blood cancer in adults and its incidence increases with age, with a poor prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2020 Category: Cancer & Oncology Source Type: news

Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
TOKYO, Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus azacitidine versus ... Biopharmaceuticals, Oncology Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2020 Category: Pharmaceuticals Source Type: news

Novel combination therapy may help overcome mTOR drug resistance in AML
(Cincinnati Children's Hospital Medical Center) Despite high hopes, mTOR inhibitors have not shown much success against acute myeloid leukemia. But a study in PNAS led by experts at Cincinnati Children's suggests a combination therapy may prove more effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Integrated Palliative and Oncology Care Improves QOL in Leukemia
FRIDAY, Dec. 18, 2020 -- For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, there are substantial improvements in quality of life (QOL) and psychological distress with integrated palliative and oncology care (IPC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Palliative care improves quality of life for patients with advanced blood cancer
(Massachusetts General Hospital) A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Why Do Black Patients Fare Worse With Blood Cancer Than Whites?
FRIDAY, Dec. 11, 2020 -- A pair of studies shed new light on why a relatively rare blood cancer— acute myeloid leukemia (AML)— is more deadly among Black patients. The takeaways: Where patients live and their access to quality health... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 11, 2020 Category: General Medicine Source Type: news

ASH: Black Race Linked to Poorer Survival in AML
TUESDAY, Dec. 8, 2020 -- Self-reported patient race is the most important factor associated with poorer survival in patients with acute myeloid leukemia (AML), according to a study presented at the annual meeting of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Chemotherapy and blinatumomab improves survival for patients with B-cell acute lympho
(University of Texas M. D. Anderson Cancer Center) A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Patti Payne: AML survivor returns home after bone marrow transplant, grateful for milestones
What ’s on your gratitude list for Thanksgiving and into the holidays? In the face of life-threatening challenges Ryan Dwyer, 40, is grateful for a long list of things. Gratitude is at the very fiber of his being. This Kenmore man just underwent a bone marrow transplant for acute myeloid leukemia — his second round of this aggressive disease. He thought he beat it the first time, but learned in mid-2020 it had returned with a vengeance, and thus the more drastic treatment was needed. Dwyer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 25, 2020 Category: Biotechnology Authors: Patti Payne Source Type: news

Patients and Physicians ’ Priorities Around AML Decisions in Older Patients Misaligned Patients and Physicians ’ Priorities Around AML Decisions in Older Patients Misaligned
Patients with acute myeloid leukaemia find decision-making around care is often not aligned with their clinician ’s views. Lack of medication options and emotional trauma play a role in poor decision-making.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Predictors of Late Effects in Young AML Survivors Explored
MONDAY, Nov. 23, 2020 -- Many adolescent and young adult (AYA) survivors of acute myeloid leukemia (AML) experience late effects, with the most common being endocrine, cardiovascular, and respiratory, according to a study published online Nov. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Beat AML: Precision Medicine Superior to SOC Beat AML: Precision Medicine Superior to SOC
Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

Young survivors of acute myeloid leukemia have long-term complications from treatment
(University of California - Davis Health) Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found. The most common complications were cardiovascular, endocrine and respiratory diseases. The complications - known as late effects - were more present among non-white AYA patients and those living in more deprived neighborhoods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2020 Category: Cancer & Oncology Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites
Ionizing radiation causes acute radiation syndrome, which leads to hematopoietic, gastrointestinal, and cerebrovascular injuries. We investigated a population of mice that recovered from high-dose radiation to live normal life spans. These "elite-survivors" harbored distinct gut microbiota that developed after radiation and protected against radiation-induced damage and death in both germ-free and conventionally housed recipients. Elevated abundances of members of the bacterial taxa Lachnospiraceae and Enterococcaceae were associated with postradiation restoration of hematopoiesis and gastrointestinal repair. The...
Source: ScienceNOW - October 29, 2020 Category: Science Authors: Guo, H., Chou, W.-C., Lai, Y., Liang, K., Tam, J. W., Brickey, W. J., Chen, L., Montgomery, N. D., Li, X., Bohannon, L. M., Sung, A. D., Chao, N. J., Peled, J. U., Gomes, A. L. C., van den Brink, M. R. M., French, M. J., Macintyre, A. N., Sempowski, G. D. Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Survival Rate for Acute Lymphoblastic Leukemia
Title: Survival Rate for Acute Lymphoblastic LeukemiaCategory: Diseases and ConditionsCreated: 10/23/2020 12:00:00 AMLast Editorial Review: 10/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 23, 2020 Category: Cancer & Oncology Source Type: news

' Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL
Chemo-free targeted therapy yielded high rates of molecular response,"impressive" survival at 18 months with few toxic effects in a phase 2 trial of adults with Ph+ acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
             Basel, 19 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA ’s accelerated approval pro...
Source: Roche Media News - October 19, 2020 Category: Pharmaceuticals Source Type: news

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
             Basel, 19 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA ’s accelerated approval pro...
Source: Roche Investor Update - October 19, 2020 Category: Pharmaceuticals Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
South San Francisco, CA -- October 16, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2020 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Genomic markers of midostaurin drug sensitivity in leukemia patients
(Impact Journals LLC) Oncotarget Volume 11, Issue 29 reported that acute myeloid leukemia is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2020 Category: Cancer & Oncology Source Type: news

Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Financing to advance mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, and potential best-in-class therapy for AML patients DUBLIN, Oct. 12, 2020 -- (Healthcare Sales & Marketing Network) -- Priothera Limited, a clinical stage company... Biopharmaceuticals, Oncology, Venture Capital, Personnel Priothera, mocravimod, sphingosine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 12, 2020 Category: Pharmaceuticals Source Type: news

Factors Associated With Suicide in Leukemia Identified
FRIDAY, Oct. 9, 2020 -- Male sex, older age at diagnosis, White race, and having acute myeloid leukemia are risk factors associated with suicide among patients with leukemia, according to a study published online Oct. 6 in Cancer Medicine. Haohui... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 9, 2020 Category: Pharmaceuticals Source Type: news

Measurable Residual Disease Negativity Tied to Survival in AML
THURSDAY, Oct. 8, 2020 -- For patients with acute myeloid leukemia (AML), achieving measurable residual disease (MRD) negativity is associated with improved survival, according to a review and meta-analysis published online Oct. 8 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 8, 2020 Category: Pharmaceuticals Source Type: news

Orthopedic Problems in Children Can Be the First Sign of ALL Orthopedic Problems in Children Can Be the First Sign of ALL
The diagnosis of acute lymphoblastic leukemia (ALL) can be delayed because of vague presentation and normal hematological results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 2, 2020 Category: Cancer & Oncology Tags: Pediatrics News Source Type: news

New NCCN resource for understanding childhood leukemia
(National Comprehensive Cancer Network) NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 23, 2020 Category: Cancer & Oncology Source Type: news

Inherited genetic variant influences response to leukemia treatment for some children
(St. Jude Children's Research Hospital) St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves First Maintenance Therapy for AML FDA Approves First Maintenance Therapy for AML
The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia
FDA approved azacitidine tablets (ONUREG ®, Celgene Corporation) for acute myeloid leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology. Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Guidance for Industry: Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
THURSDAY, Aug. 13, 2020 -- Overall survival is longer and the incidence of remission is higher among previously untreated, older patients with acute myeloid leukemia (AML) who receive azacitidine plus venetoclax versus azacitidine alone, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

Azacitidine + Venetoclax Combo Benefits Older Patients With AML Azacitidine + Venetoclax Combo Benefits Older Patients With AML
The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news